» Articles » PMID: 29997436

Real World Data: an Opportunity to Supplement Existing Evidence for the Use of Long-established Medicines in Health Care Decision Making

Overview
Publisher Dove Medical Press
Specialty Health Services
Date 2018 Jul 13
PMID 29997436
Citations 91
Authors
Affiliations
Soon will be listed here.
Abstract

Evidence from medication use in the real world setting can help to extrapolate and/or augment data obtained in randomized controlled trials and establishes a broad picture of a medication's place in everyday clinical practice. By supplementing and complementing safety and efficacy data obtained in a narrowly defined (and often optimized) patient population in the clinical trial setting, real world evidence (RWE) may provide stakeholders with valuable information about the safety and effectiveness of a medication in large, heterogeneous populations. RWE is emerging as a credible information source; however, there is scope for enhancements to real world data (RWD) sources by understanding their complexities and applying the most appropriate analytical tools in order to extract relevant information. In addition to providing information for clinicians, RWE has the potential to meet the burden of evidence for regulatory considerations and may be used in approval of new indications for medications. Further understanding of RWD collection and analysis is needed if RWE is to achieve its full potential.

Citing Articles

Real-world pharmacovigilance of ofatumumab in multiple sclerosis: a comprehensive FAERS data analysis.

Chen H Front Pharmacol. 2025; 15:1521726.

PMID: 39917326 PMC: 11799251. DOI: 10.3389/fphar.2024.1521726.


Racial/ethnic differences in survival and treatment response with PD-1/PD-L1 inhibitors in resectable non-small cell lung cancer: a meta-analysis of randomized controlled trials.

de Moraes F, Pasqualotto E, Rodrigues A, Burbano R Eur J Clin Pharmacol. 2024; 81(1):139-150.

PMID: 39542906 DOI: 10.1007/s00228-024-03777-4.


Inflammation‑based prognostic markers in patients with advanced or recurrent gastric cancer treated with nivolumab: Tokushukai REAl‑world Data project 02 (TREAD 02).

Shimoyama R, Imamura Y, Uryu K, Mase T, Ohtaki M, Ohtani K Mol Clin Oncol. 2024; 21(6):90.

PMID: 39421231 PMC: 11484223. DOI: 10.3892/mco.2024.2788.


Real-world effectiveness of first- and second-line anti-angiogenesis therapy in RCC: analysis of a UK-based population.

Waddell T, Pillai M, Armitage K, Graham D, Moran M, Dilleen M Future Oncol. 2024; 20(33):2547-2558.

PMID: 39382446 PMC: 11534105. DOI: 10.1080/14796694.2024.2385882.


A Nationwide Physical Activity Intervention for 654,500 Adults in Singapore: Cost-Utility Analysis.

Ang G, Tan C, Teerawattananon Y, Muller-Riemenschneider F, Chen C JMIR Public Health Surveill. 2024; 10():e46178.

PMID: 39365682 PMC: 11468974. DOI: 10.2196/46178.


References
1.
Bhatt A . Evolution of clinical research: a history before and beyond james lind. Perspect Clin Res. 2011; 1(1):6-10. PMC: 3149409. View

2.
Booth C, Tannock I . Randomised controlled trials and population-based observational research: partners in the evolution of medical evidence. Br J Cancer. 2014; 110(3):551-5. PMC: 3915111. DOI: 10.1038/bjc.2013.725. View

3.
Lis Y, Roberts M, Kamble S, Guo J, Raisch D . Comparisons of Food and Drug Administration and European Medicines Agency risk management implementation for recent pharmaceutical approvals: report of the International Society for Pharmacoeconomics and outcomes research risk benefit management.... Value Health. 2012; 15(8):1108-18. DOI: 10.1016/j.jval.2012.06.019. View

4.
Guyatt G, Oxman A, Vist G, Kunz R, Falck-Ytter Y, Alonso-Coello P . GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008; 336(7650):924-6. PMC: 2335261. DOI: 10.1136/bmj.39489.470347.AD. View

5.
Holtorf A, Watkins J, Daniel Mullins C, Brixner D . Incorporating observational data into the formulary decision-making process--summary of a roundtable discussion. J Manag Care Pharm. 2008; 14(3):302-8. PMC: 10437774. DOI: 10.18553/jmcp.2008.14.3.302. View